ARCHIVES

AACR Statement on Precancers Plays Key Role in NCI Agenda

This article is from The Cancer Letter archive.

Vol. 29 No. 22 | May 30, 2003

Download PDF Visit The Full Archive

Related Articles

Revlimid Extends Time To Progression Compared To Placebo In Phase III Trial

December 25, 2009

R.S.K. Young Quits As FDA Oncology Group Leader

July 11, 1980

New Awards for New Investigators To Replace R-23 Grants

November 8, 1985

In Brief: Durant New President Of AACI, Ultmann Named President-Elect; Farber Center Gets New Name

February 4, 1983

NCI Starts “Exceptional Responders” Study

September 26, 2014

NCCS Networker Volume 1 Issue 1, March 1987

March 12, 1987